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Background: Vogt-Koyanagi-Harada (VKH) disease and sympathetic ophthalmia (SO) are both autoimmune
disorders targeting melanin-bearing cells, even though their etiologies are different. Both shared many ocular and
systemic manifestations, including integumentary findings. Most of the literature focused on the ocular
manifestations and related treatment. Alopecia was seldom mentioned.
Findings: We report one case of VKH disease and one case of SO. Both developed severe alopecia and early sunset
glow fundus, which are probably due to incomplete treatment. Fortunately, the alopecia improved soon after
systemic steroid treatment.
Conclusions: Early and complete treatments are important in the management of VKH or SO and prevent
integumentary manifestation. Alopecia can be reversible after steroid treatment in time.Findings
Introduction
Vogt-Koyanagi-Harada (VKH) disease and sympathetic
ophthalmia (SO) are autoimmune disorders, targeting
melanin-bearing cells. Both diseases are characterized by
immunologic dysregulation [1]. The reports from litera-
ture suggest that the disorders have different etiologies
with similar ocular and systemic manifestations [1-3].
According to the diagnostic criteria, patients with VKH
should have no history of surgery or trauma. In addition,
neurological and integumentary findings are the neces-
sary condition to fit the complete form of VKH. Ocular
depigmentation was defined as the late manifestation of
VKH cases [4]. Ocular depigmentation and integument-
ary findings (alopecia, poliosis, and vitiligo) are supposed
to be the sequelae of destruction of melanin-bearing
cells by the autoimmune attack. Contrary to VKH, alo-
pecia was seldom mentioned in case of SO [3,5,6]. Based
on its pathogenesis, it is reasonable to expect integu-
mentary manifestations in SO case. Here we report two
interesting cases presenting reversible alopecia in a VKH
patient and an SO patient.* Correspondence: sjsheu@vghks.gov.tw
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A 45-year-old female visited our clinic on July 10, 2011
with the chief complaint of acute onset of blurred vision
in both eyes for 1 week. There was no other related
symptom except tinnitus. She had history of drug abuse
and radial keratotomy for myopia 20 years ago (−2D
before operation). Otherwise, she was quite well system-
ically. On presentation, her vision was 6/60 (6 + 4.75,
−1.75 × 175) in the right eye and 6/60 (+4.25, −2.5 ×
170) in the left eye. Ophthalmic examination showed
mild anterior chamber reaction and multiple lobules of
serous retinal detachments in both eyes (Figure 1A,B).
Fluorescent angiography (FAG) showed multiple pin-
point hyperfluorescent spots with severe leakage and
pooling at late phase in both eyes (Figure 1C,D). Vogt-
Koyanagi-Harada disease was the impression based on
the clinical pictures and characteristic FAG findings.
Admission was scheduled on July 11 due to personal
reason. Unfortunately, she called at ER for fever (38°C),
chills, severe headache, and neck rigidity on July 10.
Lumbar puncture showed pleocytosis (WBC count, 390
mm3; RBC count, 20 mm3; Pandy’s test (+); protein, 139;
sugar, 70). No pigment-laden macrophage was found in
the cytological study. Brain MRI was negative for space-
occupying lesions or inflammation. Systemic workup in-
cluding general physical examination, complete blood
counting, differential classification, blood biochemicalan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Clinical manifestations of the patient with VKH. (A,B) Initial fundus examination showed multiple bullous retinal detachment in
both eyes. (C,D) Fundus fluorescent angiography showed multiple pinpoint leakage and late dye pooling in both eyes. (E,F) Remarkable sunset
glow fundus in both eyes. (G) Severe alopecia developed 5 months after onset. (H) Alopecia improved after systemic steroid.
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immunodeficiency virus, venereal disease research la-
boratory test, herpes virus immunoglobulin, and chest
radiography were within normal ranges. The initial
report of tuberculosis (TB) polymerase chain reaction
(PCR) from aqueous fluid was negative. Systemic intra-
venous methylprednisolone pulse (MTP) therapy was
given 250 mg every 6 h for 3 days. The meningismus
and serous detachment resolved after pulse (MTP)
therapy and the vision improved a lot. Repeated cerebro-
spinal fluid (CSF) analysis on July 14 showed decreased
pleocytosis (WBC count, 241 mm3; RBC count, 1 mm3,
Pandy’s test (−); sugar, 101). Just after completing MTPtherapy, the official report of TB PCR from the outside
laboratory announced positive result. Infection specialist
was consulted, who repeated the TB PCR on CSF.
Although the results of tuberculin test, PCR, and culture
on CSF were all negative for TB, the internist decided to
give her four combined anti-tuberculosis medication for
6 months. Besides, oral and topical prednisolone was
tapered gradually. However, the patient did not comply
well with the treatment due to the side effects of steroid
and allergic reaction to ethambutol. Progressive hair loss
was noted 5 months later (Figure 1G). At this time, the
vision was 6/10 (−1.25, −1.5 × 75) in the right eye and
6/12 (−2.5, −1.0 × 70) in the left eye. There was
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fundus showed sunset glow appearance with multiple
small atrophic lesions (Figure 1E,F). The patient agreed
to receive and comply with large dose of systemic
steroid (1 mg/kg) again. The alopecia improved soon
after repeated systemic steroid (Figure 1H), but recur-
rent anterior uveitis persisted and remarkable sunset
glow fundus developed in both eyes. Intravitreal injec-
tion of Ozurdex (dexamethasone implant 700 μg,
Allergan Inc., Irvine, USA) was given in both eyes to
replace the systemic steroid as the patient lost compli-
ance again ever since her alopecia improved. TheFigure 2 Clinical manifestations of the patient with sympathetic opht
lens opacity, and vitreous hemorrhage. (B) Slit lamp biomicroscopic examin
the left eye. (C) Optical computerized tomography of left eye showed sero
sunset glow fundus with multiple atrophic lesions. (E) Severe alopecia deve
after systemic steroid treatment.anterior uveitis was controlled after dexamethasone
(Ozurdex) implant in both eyes.
Case 2
A 41-year-old female visited our emergency room for
blurred vision in her right eye after blunt injury inflicted
by her boyfriend two days ago. She has past history of
hyperthyroidism after treatment. At presentation, there
was light perception only in the right eye and 20/30
(naked eye) in her left eye. Ophthalmic examination
showed severe subconjunctival hemorrhage and hyphema
with exudates in the anterior chamber of right eye. Thehalmia. (A) Atrophic change of right eye with posterior synechiae,
ation showed keratic precipitate, trace cell in the anterior chamber in
us retinal detachment. (D) Fundus examination showed remarkable
loped 2 months after trauma in the right eye. (F) Alopecia improved
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Her left eye was unremarkable. Orbital CT showed irregu-
lar posterior contour of the right eye and surgical explor-
ation was suggested under the impression of highly
suspected eye ball rupture. Unfortunately, she refused and
lost to follow up until 1 month later when she came back
for blurred vision in her left eye. Ophthalmic examination
showed no light perception and bulbar atrophy in the
right eye, 6/10 with keratic precipitate, trace cell in the
anterior chamber, and disk swelling in the left eye
(Figure 2A,B). MTP pulse therapy was suggested based on
the diagnosis of sympathetic ophthalmia. The patient re-
fused admission and received topical and oral prednisol-
one (15 mg TID) instead, then lost to follow up for
another 2 weeks when the vision deteriorated to 6/60 with
serous retinal detachment (Figure 2C). The patient did
not show up for scheduled MTP treatment again. She
came back 1 month later with sunset glow fundus in the
left eye and severe alopecia (Figure 2D,E). According to
the patient, she never received oral steroid treatment by
the dermatologist due to alopecia before this visit. The
alopecia resolved after intensive oral steroid treatment
(Figure 2F). The best corrected vision was no light percep-
tion in the right eye and 6/10 in the left eye 5 months after
trauma. There were multiple recurrences of anterior
uveitis with remarkable fundus depigmentation in her
left eye.
Discussion
Early and complete treatment is the key in the management
of both VKH and SO diseases. Even with the development
of new immunomodulatory agents, systemic steroid is the
mainstay of treatment [7]. Lai reported that the duration of
at least 6 months is a key factor in reducing chances of re-
currence [8]. Other series reported that submaximal doses
of inflammation suppressive therapy are sufficient to sup-
press clinically apparent disease but not the underlying le-
sion process. This explains the propensity for sunset glow
fundus in a seemingly controlled disease [9].
Although integumentary manifestation is one of the
major diagnostic criteria in VKH disease, the incidence
of alopecia or poliosis is much less than the ocular man-
ifestations [5,10-13]. In our previous reports, the inci-
dence of integumentary manifestation was 15.4%, but
only 3.2% in those whose who were treated within 1
month [11,14]. It is supposed to be the results of depig-
mentation of melanin-bearing cells as it is seen in the
sunset glow fundus. As both VKH and SO are speculated
to have an underlying T cell-mediated autoimmunity to
uveal/retinal antigen, the melanin-bearing hair follicles
may be targeted if the inflammation was not controlled
well enough. Immediate immunosuppression by inten-
sive steroid therapy could suppress the inflammation
and prevent the total destruction of the hair cells. Thepresentation might be also influenced by the complete-
ness of treatment [15]. The increased awareness of diag-
nosis and treatment of VKH might explain the rare case
of severe alopecia. The consequent change of alopecia or
poliosis had seldom been mentioned in the literature.
There was one report about partially reversible sensori-
neural hearing loss in VKH disease from Ondrey et al.
[16]. Our cases were obviously under-treated before the
development of alopecia. Fortunately, the alopecia re-
solved after systemic steroid therapy. Their experiences
can be used as one of the examples to persuade patients
with VKH and SO to keep on complete treatment.
Conclusion
Early and complete treatments are important in the
management of VKH or SO and prevent integumentary
manifestation. Alopecia can be reversible after steroid
treatment in time.
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